146 related articles for article (PubMed ID: 32311595)
1. Anti-recurrence/metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system.
Yang J; Pan S; Gao S; Dai Y; Xu H
Biomaterials; 2020 Aug; 249():120054. PubMed ID: 32311595
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents.
Liu Y; Li Y; Yu S; Zhao G
Curr Drug Targets; 2012 Oct; 13(11):1432-44. PubMed ID: 22876886
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
5. Selenocysteine in mammalian thioredoxin reductase and application of ebselen as a therapeutic.
Ren X; Zou L; Lu J; Holmgren A
Free Radic Biol Med; 2018 Nov; 127():238-247. PubMed ID: 29807162
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin reductase as a pathophysiological factor and drug target.
Becker K; Gromer S; Schirmer RH; Müller S
Eur J Biochem; 2000 Oct; 267(20):6118-25. PubMed ID: 11012663
[TBL] [Abstract][Full Text] [Related]
7. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.
Ganther HE
Carcinogenesis; 1999 Sep; 20(9):1657-66. PubMed ID: 10469608
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
9. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
11. Selenium Atom-Polarization Effect Determines TrxR-Specific Recognition of Metallodrugs.
Chen M; Cao W; Wang J; Cai F; Zhu L; Ma L; Chen T
J Am Chem Soc; 2022 Nov; 144(45):20825-20833. PubMed ID: 36318653
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
13. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Lu J; Chew EH; Holmgren A
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
[TBL] [Abstract][Full Text] [Related]
14. Promotion of HeLa cells apoptosis by cynaropicrin involving inhibition of thioredoxin reductase and induction of oxidative stress.
Liu T; Zhang J; Han X; Xu J; Wu Y; Fang J
Free Radic Biol Med; 2019 May; 135():216-226. PubMed ID: 30880248
[TBL] [Abstract][Full Text] [Related]
15. A Diselenide Turn-On Fluorescent Probe for the Detection of Thioredoxin Reductase.
Mafireyi TJ; Laws M; Bassett JW; Cassidy PB; Escobedo JO; Strongin RM
Angew Chem Int Ed Engl; 2020 Aug; 59(35):15147-15151. PubMed ID: 32449244
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Thioredoxin System as a Strategy for Cancer Therapy.
Bian M; Fan R; Zhao S; Liu W
J Med Chem; 2019 Aug; 62(16):7309-7321. PubMed ID: 30963763
[TBL] [Abstract][Full Text] [Related]
17. Effects of Mammalian Thioredoxin Reductase Inhibitors.
Arnér ESJ
Handb Exp Pharmacol; 2021; 264():289-309. PubMed ID: 32767140
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
19. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein.
Cenas N; Nivinskas H; Anusevicius Z; Sarlauskas J; Lederer F; Arnér ES
J Biol Chem; 2004 Jan; 279(4):2583-92. PubMed ID: 14604985
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR.
Hu J; Chen L; Lu Z; Yao H; Hu Y; Feng L; Pang Y; Wu JQ; Yu Z; Chen WH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
